Archive for June, 2008

Two Men Fined For Selling Erectile Dysfunction Drugs, UK

Monday, June 16th, 2008

Latest News For This Category
Correlation Between Erectile Dysfunction And LUTS The AUA Lecture
19 Apr 2008
A Mixed Set Of Results From 5-Alpha-Reductase Inhibitors And Reduced Prostate Cancer Risk
16 Apr 2008
Federal Authorities Seize More Than 100,000 Dollars Of Unapproved Drugs Marketed As "Natural Supplements"
10 Apr 2008
View more news…
Latest Videos for Erectile Dysfunction
Penile Pump Expectations
For many men suffering from erectile dysfunction, the solution to their problem lies not in medications or sex therapy but rather in a surgically implanted device called an Internal Penile Pump…
Penile Pump Implants
generic diflucan online buy Since its invention, the internal penile pump has helped over 250,000 men suffering from erectile dysfunction. Choosing this option is a major decision and many are concerned about its long-term effects. Join our panel of doctors, patients and a partner as they share their post-operation…
View more videos…
Advertisements
Add Your Advertisement Here
Most Read Articles From The Last 7 Days
Vitamin Supplements Don’t Help You Live Longer, Study
16 Apr 2008
Life Expectancy Disparities Increasing In The US
22 Apr 2008
Diet
Designed To Lower Blood Pressure May Also Fight Heart Disease And Stroke
16 Apr 2008
Polycarbonate Baby Bottles Containing Bisphenol A May Become Banned In Canada
19 Apr 2008
Baby’s Gender Linked To Mother’s Diet At Conception
23 Apr 2008
Most Popular Categories
public health
neurology
nutrition
cancer
cardiovascular
hiv
diabetes
dermatology
obesity
alcohol
psychology
women’s health
infectious diseases
pediatrics
breast cancer
urology
pregnancy
gastrointestinal
pain
respiratory
prostate
bones
depression
smoking
medical devices
health insurance
medicare
hypertension
stem cell research
biology
alzheimer’s
sexual health
sleep
abortion
genetics
allergy
autism
eye health
adhd
it
multiple sclerosis
sports medicine
pharma industry
dentistry
liver disease
anxiety
arthritis
seniors
cholesterol
mrsa
Generic acomplia pills no prescription | generic cipro online buy | Buy generic zithromax

Are You Allergic To Your Home? Proper Spring Cleaning Can Combat Allergens

Monday, June 16th, 2008

As allergy-sufferers nationwide tackle their nose nemeses or keep scratching their heads - literally - in the quest to identify the source of their allergen angst, they can consider these tips for combating allergies in the home.
The most common allergens are dust mites and animal dander found mostly inside, not outside, the home sweet home. The Asthma and Allergy Foundation of America (AAFA) also lists cockroaches as common allergens, especially in inner cities or southern parts of the United States.
Perfume, room deodorizers, harsh cleaning chemicals, paint, and talcum powder are also known allergens and asthma triggers to reduce or avoid altogether.
May presents a great opportunity to:
- Replace air conditioning filters to help reduce the dust settlement,
- Incorporate humidifiers or other air filters in the home to help prevent dust mites
- Employ the use of non-toxic or natural household cleaners
- Replace artificially scented items with naturally scented oils and soy-based products
- Consider future use of Low-VOC paint
The AAFA states that allergy is the 5th leading chronic disease in the U.S. among all ages, and the 3rd most common chronic disease among children under 18 years old (according to the National Academy on an Aging Society).
"There is little we can do about external allergens, but there are many preventative measures we can take inside our homes," said Dr. Alan Greene, renowned medical expert, author and speaker. "It is important to avoid obsessively over cleaning your home, therefore preventing allergen immunities from forming. Instead, use non-toxic cleaning products and omit other irritants from the immediate environment."
To help combat allergens, Seventh Generation offers a full range of cleaning products that are free of fragrances, dyes and toxins - perfect for those cleaning a home with an allergy or asthma sufferer. Seventh Generation Free & Clear Starter Kits are available to help create and maintain a healthy home.
For more on National Allergy and Asthma Awareness Month please visit the Asthma and Allergy Foundation of America at
About Seventh Generation
Buy generic propecia For 20 years, the closely held Burlington, Vermont company has been at the forefront of a cultural change in consumer behavior and business ethics. One of the country’s first self-declared "socially responsible" companies, Seventh Generation is committed to becoming the world’s most trusted brand of authentic, safe, and environmentally responsible products for a healthy home. Seventh Generation markets and distributes through natural food stores, supermarkets, on-line stores like Amazon.com and mail-order catalogs in the United States and Canada.
Seventh Generation
Buy levitra without prescription | Buy generic propecia | Generic fosamax pills no prescription

Correlation Between Erectile Dysfunction And LUTS The AUA Lecture

Sunday, June 15th, 2008

UroToday.com - Dr. Kevin McVary (Chicago) presented the AUA lecture. generic soma online buy The incidence of ED increases to over 60% by age 60. He showed data that ED increases with increasing severity of LUTS, independent of age. Across all age groups, increasing LUTS correlated with worse ED even after adjusting for other factors such as diabetes mellitus. This suggests a common pathophysiology or causal relationship between ED and LUTS.
In the MTOPS data, sexual function domains were stratified against AUA symptom indices and all sexual function domains correlated with LUTS. Prostate volume also correlated with ED as increasing size and worsening ED were linked. Several theories may explain these findings. Nitros oxide (NO) can be reduced by smoking, diabetes, etc. and result in prostatic hyperplasia that contributes to LUTS. In a canine prostate model, exposure to NO results in increased relaxation of smooth muscle, consistent with the hypothesis. Dr. McVary’s research has shown decreased NO as men age. The enzyme PDE-5 in the prostate and bladder is increased and may contribute to ED. Experimental models of PDE-5 inhibitors result in increased smooth muscle relaxation.
He spoke about using the PDE-5 inhibitor concept to treat LUTS. A placebo run-in phase is important in LUTS trials. Sildenafil was tested in a combined ED/LUTS trial, and LUTS scores improved by over 6 points. Both obstructive and irritative scores improved. He cited Dr. Steif’s vardinafil study that also demonstrated an improvement in LUTS. Despite symptom improvement, Dr. McVary did not find any improvement in urinary flow rate.
He also spoke about atherosclerosis induced chronic ischemia causing bladder and penile fibrosis and contributing to both voiding and erectile symptoms. Another theory is that increased autonomic activity correlates to ED and LUTS. He presented data in patients to support this correlation. A causal relationship was not demonstrated. Increased sympathetic tone from obesity, physical inactivity and other causes lead to effects on erectile function and LUTS.
Presented by: Kevin McVary, MD, at the European Association of Urology - 23rd Annual EAU Congress - March 26 - 29, 2008 - Milan, Italy
Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to:
www.urotoday.com
Copyright © 2008 - UroToday
Buy fosamax pills | generic clomid online buy | Buy propecia without prescription

Erectile Dysfunction And Diabetes

Sunday, June 15th, 2008

"Men with diabetes who are having trouble keeping an erection could be at increased risk of serious heart problems", BBC News reported. It said that a study has found that those with erectile dysfunction are twice as likely as other men with diabetes to develop heart disease. This finding could apparently be used to "alert both patients and healthcare providers to the future risk of coronary heart disease".
This study followed 2,306 diabetic men for four years and found that the men with erectile dysfunction were 1.58 times more likely to have a cardiac event (fatal or non-fatal heart attack or surgery for heart disease). It has some potential weaknesses, for example it might not have used the most accurate method for classifying erectile dysfunction, some of the participants may already have had heart disease before the study began, and other drugs they were taking could have had an effect.
Despite its shortcomings however, this research corroborates what other studies have suggested. It suggests that an assessment of erectile dysfunction could be useful when assessing the risk of heart disease in men with diabetes.
Where did the story come from?
Dr Ronald Ching-Wan Ma and colleagues from the Chinese University of Hong Kong carried out the research. The study was supported by an MSD University Grant and by the Hong Kong Foundation for Research and Development in Diabetes. The study was published in the Journal of the American College of Cardiology.
What kind of scientific study was this?
It is known that men with diabetes have a higher risk of erectile dysfunction and its prevalence increases with age, and duration and severity of the diabetes. Previous research has suggested a close association between erectile dysfunction and atherosclerosis, while other studies have indicated that it could be used as an indicator of coronary, peripheral or cerebrovascular disease.
The authors of this study aimed to be the first to use a prospective analysis to see if the presence of erectile dysfunction can be used as a predictor of adverse cardiovascular events such as coronary heart disease. In this prospective cohort study, the researchers included men with diabetes at the Prince of Wales Hospital Diabetes Centre, Hong Kong between 1995 and 2005. The suitability of 3,640 men who had been referred to the centre was assessed. The researchers excluded any men who had type 1 diabetes, cardiovascular disease at the start of the study (through medical history or abnormal ECG or stress test) or for whom there was incomplete information on erectile dysfunction.
This left 2,306 men with type 2 diabetes who had been assessed for the complications and risk factors associated with their condition. The participants had a series of clinical and laboratory assessments, including at least two urine collections to measure protein levels. This would give an indication of kidney function. In addition, they were asked whether they suffered from erectile dysfunction (they could answer yes or no).
The researchers followed up the participants for an average of four years, during which time they collected data on hospital admissions and mortality. In Hong Kong, all residents have a unique identification number and researchers used this to link hospital records and diagnoses (e.g. death from acute heart attack or other coronary cause, or non-fatal cardiac events) with the participants’ original data from the study. In this way, they could see if there was an association between heart problems and erectile dysfunction in men with diabetes.
When analysing this association, the researchers took into account other factors that can have an influence on erectile dysfunction or heart disease, including; smoking history, age, how long they had diabetes, use of blood pressure and other medications, blood pressure, blood cholesterol, BMI and waist circumference.
What were the results of the study?
The researchers found that at the beginning of the study, 27% of the men reported having erectile dysfunction. These men were older, had higher blood pressure, had had diabetes for longer, and had higher blood cholesterol.
During approximately four years of follow up, new cardiac events occurred in about 5% of men. Men with erectile dysfunction were 1.58 times (HR 1.58, 95% CI 1.08 to 2.30) more likely than men without erectile dysfunction to experience a cardiac event during follow up. This analysis took into account some other factors that might be responsible for the association. Erectile dysfunction was not the only factor that increased cardiac events; age, duration of diabetes, high levels of protein in urine, and use of medications for high blood pressure were also independently associated.
What interpretations did the researchers draw from these results?
The researchers conclude that there is an association between erectile dysfunction and new cardiac events in men with type 2 diabetes. They say that erectile dysfunction is a "surrogate marker" for future heart problems.
What does the NHS Knowledge Service make of this study?
The researchers raise several possible problems associated with this study. These should be kept in mind when interpreting the results:
- Studies that assess sensitive topics such as erectile dysfunction are difficult to carry out accurately. The men who took part might not have fully reported the extent of their erectile dysfunction, leading to an underestimation of the problem. For example, if a large number of men with erectile dysfunction did not report it and were free of cardiac events during follow up, their results may have swayed the conclusions to being not significant. On the other hand, if some men didn’t report their erectile dysfunction and experienced cardiac events, the study will have underestimated the strength of the association.
- The researchers say that the single question they asked to determine whether a man suffered from erectile dysfunction, may not have been as appropriate as using other questionnaires that ask more objective questions. If men with more severe dysfunction were more likely to answer yes, then the study’s findings would be biased.
- The study was carried out in Hong Kong and the men who took part might not be representative of men from other countries. In particular, it’s unclear if the findings from the study are applicable to men in western countries as lifestyle factors across cultures may contribute differently to a person’s overall risk profile.
- Though the researchers tried to exclude any men with evidence of cardiac problems, they say that "comprehensive cardiac assessments were not routinely performed in asymptomatic patients". This means that people with no obvious clinical symptoms could have been included. If this were the case, the researchers had no way of identifying those whose erectile dysfunction was actually a result of their heart problems.
- This study suggests that there are several independent factors associated with erectile dysfunction - namely age, use of medications, duration of diabetes and high protein levels in urine. Buy lasix without prescription Determining which of these is the most important is difficult. Future studies should particularly assess the contributions made by drugs such as lipid lowering statins that are known to cause erectile dysfunction. Most people with diabetes will be on multiple drugs with the potential to cause this condition.
It is known that men with diabetes are more likely to have erectile dysfunction and that this problem is associated with atherosclerosis (narrowing and hardening of the arteries). This study provides data to support the association that other studies have found between erectile dysfunction and cardiac problems. It is important that these results are confirmed in larger populations and across cultures.
Links to the headlines
Sex problems ‘may be heart alert’. BBC News, May 21 2008
Links to the science
Erectile Dysfunction Predicts Coronary Heart Disease in Type 2 Diabetes.
R C-W Ma, So W-Y, Yang X, et al.
J Am Coll Cardiol 2008; 51: 2045-2050
This news comes from NHS Choices
Buy generic ultram | Generic propecia pills no prescription | Buy lasix pills

Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL 3994

Saturday, June 14th, 2008

Palatin Technologies,
Inc. (Amex: PTN) announced that dosing has been initiated in a Phase
2a clinical study of PL-3994, a novel, long-acting natriuretic peptide
receptor A agonist, in subjects with controlled hypertension.
The study is placebo-controlled and double-blinded, and will include up
to five cohorts receiving escalating doses. As many as 35 subjects will be
included, with six active subjects and one placebo subject per dose cohort.
Subjects passing screening are admitted to a research clinic, placed on a
controlled diet and have baseline blood pressures and laboratory values
monitored for 24 hours. The next morning, subjects receive a single dose of
PL-3994 or placebo with blood pressures and laboratory values monitored for
24 hours. Every other week, another cohort of subjects will receive a
higher dose of PL-3994 until a pre-specified blood pressure decrease is
observed.
"We are excited with our PL-3994 program’s rapid progress. Data from
these hypertensive patients will provide key indications of the compound’s
therapeutic potential," stated Dr. Trevor Hallam, Palatin’s Executive Vice
President for Research and Development. "We look forward to the completion
of this study as well as the reporting of results next quarter."
Based on the results of this study and the previously completed Phase 1
trial in healthy, non-hypertensive volunteers, a Phase 2 trial in patients
with
episodes of hypertensive urgency is planned for later this calendar
year. Palatin is also developing PL-3994 for the treatment of acute
decompensated congestive heart failure and plans to initiate a separate
Phase 2 study in these patients later this calendar year.
About Acute Systemic Hypertension
An acute elevation of blood pressure, or acute hypertension, is a
life-threatening condition that can cause permanent damage to the brain,
heart, kidneys and blood vessels. It occurs in nearly 50 percent of
patients presenting to the hospital with acute heart failure and is a
common occurrence for patients with renal dysfunction. It is critical to
rapidly manage and maintain optimal blood pressure to minimize risk of
death and damage to vital organs. Of the over 35 million people in the
United States with hypertension, over one million people each year will
have one or more acute episodes of high blood pressure, requiring treatment
in
an acute care setting.
About Congestive Heart Failure (CHF)
Currently in the U.S., CHF affects nearly 5 million people with 550,000
new cases
of CHF diagnosed each year. Despite the treatment of CHF with
multiple drugs, almost all CHF patients will experience at least one
episode of acute CHF that requires treatment with intravenous medications
in the hospital. There were over 1,100,000 hospitalizations for CHF in
2004. Congestive heart failure has tremendous human and financial costs.
Estimated direct costs in the U.S. for CHF were $29.6 billion in 2006.
About Palatin Technologies, Inc.
generic viagra online buy Palatin Technologies, Inc. is a biopharmaceutical company primarily
focused on discovering and developing targeted, receptor-specific peptide
and small molecule therapeutics, including melanocortin ("MC")-based
therapeutics. Therapeutics affecting the activity of the MC family of
receptors may have the potential to treat a variety of conditions and
diseases, including sexual dysfunction, obesity and related disorders,
cachexia, hemorrhagic shock and inflammation-related diseases. The Company
is exploring other receptor-specific therapeutics, including natriuretic
peptide receptor A ("NPRA") agonist compounds for use in treatment of acute
systemic hypertension, congestive heart failure and other diseases.
Palatin’s strategy is to develop products and then form marketing
collaborations with industry leaders in order to maximize their commercial
potential. The Company currently has collaborations with AstraZeneca and
the Mallinckrodt division of Covidien. For additional information regarding
Palatin, please visit Palatin Technologies’ website at

Forward looking Statements
Statements about the Company’s future expectations, including
statements about its development programs, proposed indications for its
product candidates, pre-clinical activities, marketing collaborations, and
all other statements in this document other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934
and as that term is defined in the Private Securities Litigation Reform Act
of 1995. The Company intends that such forward-looking statements shall be
subject to the safe harbors created thereby. Palatin’s actual results may
differ materially from those discussed in the forward-looking statements
for various reasons, including, but not limited to the Company’s ability to
fund development of its technology, ability to establish and successfully
complete clinical trials and pre-clinical studies and the results of those
trials and studies, dependence on its partners for certain development
activities, need for regulatory approvals and commercial acceptance of its
products, ability to recommence marketing and gain commercial acceptance of
NeutroSpec(R), ability to protect its intellectual property, and other
factors discussed in the Company’s periodic filings with the Securities and
Exchange Commission. The Company is not responsible for updating for events
that occur after the date of this press release.
Palatin Technologies, Inc.

generic soma online buy | Buy diflucan pills | Buy generic propecia